163 related articles for article (PubMed ID: 10649155)
1. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17beta-estradiol on lipid and lipoprotein profiles.
Lobo RA; Zacur HZ; Caubel P; Lane R
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):41-9. PubMed ID: 10649155
[TBL] [Abstract][Full Text] [Related]
2. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
Ylikorkala O; Lim P; Caubel P
Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
[TBL] [Abstract][Full Text] [Related]
3. Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women.
Curran MP; Wagstaff AJ
Drugs Aging; 2001; 18(11):863-85. PubMed ID: 11772126
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on estradiol and norgestimate as hormone replacement therapy in postmenopausal women.
Curran MP; Wagstaff AJ
Treat Endocrinol; 2002; 1(2):127-9. PubMed ID: 15765628
[TBL] [Abstract][Full Text] [Related]
5. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
6. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
Gynecol Endocrinol; 2002 Apr; 16(2):155-62. PubMed ID: 12012627
[TBL] [Abstract][Full Text] [Related]
8. Effects of E2 and E2/norgestimate hormone therapy on elevated baseline lipids.
Langer RD; Friedman AJ
J Reprod Med; 2006 Aug; 51(8):610-6. PubMed ID: 16967629
[TBL] [Abstract][Full Text] [Related]
9. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
10. Oral 17beta-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women.
Pornel B; Chevallier O; Netelenbos JC
Menopause; 2002; 9(3):171-8. PubMed ID: 11973440
[TBL] [Abstract][Full Text] [Related]
11. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
[TBL] [Abstract][Full Text] [Related]
12. Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial.
Falkeborn M; Lithell H; Persson I; Vessby B; Naessén T
Climacteric; 2002 Sep; 5(3):240-8. PubMed ID: 12419082
[TBL] [Abstract][Full Text] [Related]
13. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
[TBL] [Abstract][Full Text] [Related]
14. Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate.
Ylikorkala O; Wahlström T; Caubel P; Lane R
Acta Obstet Gynecol Scand; 2002 Jul; 81(7):654-60. PubMed ID: 12190841
[TBL] [Abstract][Full Text] [Related]
15. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women.
Bayrak A; Aldemir DA; Bayrak T; Corakçi A; Dursun P
Arch Gynecol Obstet; 2006 Aug; 274(5):289-96. PubMed ID: 16810536
[TBL] [Abstract][Full Text] [Related]
16. A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins.
März W; Gross W; Gahn G; Romberg G; Taubert HD; Kuhl H
Am J Obstet Gynecol; 1985 Oct; 153(3):287-93. PubMed ID: 2931988
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women.
Al-Azzawi F; Wahab M; Sami S; Proudler AJ; Thompson J; Stevenson J
Climacteric; 2004 Sep; 7(3):292-300. PubMed ID: 15669554
[TBL] [Abstract][Full Text] [Related]
18. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
Haarbo J; Hassager C; Jensen SB; Riis BJ; Christiansen C
Am J Med; 1991 May; 90(5):584-9. PubMed ID: 1827568
[TBL] [Abstract][Full Text] [Related]
19. Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17beta-estradiol and norethisterone acetate.
Samsioe G; Li C; Borgfeldt C; Wilawan K; Aberg A; Larsen S
Menopause; 2002; 9(5):335-42. PubMed ID: 12218722
[TBL] [Abstract][Full Text] [Related]
20. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
Hartgens F; Rietjens G; Keizer HA; Kuipers H; Wolffenbuttel BH
Br J Sports Med; 2004 Jun; 38(3):253-9. PubMed ID: 15155420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
